September 18th 2024
The FDA has approved the Eversense 365, the world’s first 1-year continuous glucose monitor, with US availability expected in late 2024.
FDA Reduces Restrictions on Diabetes Medication Rosiglitazone
November 26th 2013Following an extended review of safety data that showed no elevated risk of heart attack or death in patients taking rosiglitazone, the FDA announced it is lifting certain restrictions on the prescribing and dispensing of the drug.
Risk Indices in Perioperative Medicine: What Do They Tell Us?
Presentation at the 2013 Southern Hospital Medicine Conference reviewed the clinical application of several key risk indices, including the Revised Cardiac Risk Index and the Vascular Study Group of New England Risk Index.
Exercise Produces Cardiovascular Outcomes Similar to Drug Interventions
November 1st 2013New evidence suggests that physical activity and drug interventions are similar in terms of mortality benefits in the secondary prevention of congestive heart failure (CHF), rehabilitation after stroke, treatment of heart failure, and prevention of diabetes.
Cost of Insulin Pens Justified with Better Safety, Improved Health in Elderly Diabetics
October 2nd 2013Although pen devices are perceived to be more costly than vialed insulin, new study results indicate that elderly diabetic patients are more likely to accept pen devices and adhere to therapy, which decreases long-term complications and associated healthcare costs.
Making Group Visits Work in Your Practice
September 23rd 2013Group visits can be an especially effective tool for providing follow-up care to patients with chronic conditions, offering them increased access to clinicians and other providers, support and encouragement from their peers, and enhanced educational opportunities.
Patients with Undiagnosed Diabetes Have Worse Short-Term Cardiac Outcomes
August 9th 2013Patients who are unaware that they have diabetes may have less contact with healthcare professionals, receive less aggressive treatment, or have a poorer understanding of the disease and the actions required to treat it - all of which may be responsible for their increased risk of morbidity and mortality.